Interview with Xander Bos, General Manager, Boehringer Ingelheim B.V.
28.07.2012
Related Interviews
Europe / EMA's Emer Cooke Talks COVID Lessons, AMR & Clinical Trials
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
Interview: Karel Fol – Country Manager Benelux, Sobi, The Netherlands
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
Interview: Leo De Haan – Managing Director Benelux, Aurobindo, The…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Leadership / Bill Sibold Swaps Sanofi for Biotech Seeking First NASH FDA Approval
After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the…
MEA / Clinical Research in the UAE: Quickfire Progress & The Road Left to Travel
With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and…
Global / Top Five CROs 2023
The global contract research organization (CRO) market is estimated to be worth USD 76.6 billion in 2023 and is projected to reach USD 127.3 billion by 2028, growing at a…
